Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleome Therapeutics

Full company profile

uuid0000s8e

Namestring
Nucleome Therapeutics
Legal namestring
Nucleome Therapeutics Limited
Websiteurl
nucleome.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Nucleome Therapeutics is a UK-based preclinical biotechnology company, spun out of the University of Oxford in 2019 and headquartered in Oxford, that decodes the non-coding ('dark') genome to identify causal drug targets for immune-mediated inflammatory diseases. Its proprietary Micro Capture-C (MCC) platform provides single base-pair resolution mapping of 3D chromatin interactions, physically linking non-coding disease-associated variants to the genes they dysregulate; MCC is exclusively licensed from Oxford University and protected by US Patent No. US12,674,197 (granted July 2026), with additional patents covering its Variant Functional Validation (VFV) technology granted in 2025. The company combines this wet-lab assay with deep-learning models and its proprietary 'Nucleome Genetic Score' to produce a Disease Atlas covering hundreds of dysregulated genes across multiple inflammatory cell types, and has retrospectively demonstrated a 4x improvement in clinical success rate over industry standard for drug target selection in inflammatory diseases.

The lead in-house programme is NTP464, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint, nominated in January 2026 for chronic inflammatory diseases including rheumatoid arthritis, lupus, and IBD, with IND-enabling studies underway and Phase 1 commencement targeted for 2027. Nucleome operates a dual business model: building its own antibody pipeline while selectively partnering with pharmaceutical companies — it has a current collaboration with a major (unnamed) pharma partner — to monetize targets, biomarkers, and patient stratification insights via licensing, milestone payments, and royalties. The company is venture-backed (Series A of £37.5M closed October 2022 led by M Ventures, with Pfizer Ventures, JJDC, British Patient Capital, and Oxford Science Enterprises) and led by an experienced team including CEO Dr. Mark Bodmer (formerly SVP at GSK and CSO at Evelo Biosciences), CSO Dr. Michelle Morrow (appointed February 2026), CTO Dr. Jonny Wray, and CBO Bhavna Hunjan.

Short descriptiontext

Nucleome Therapeutics is an Oxford University spinout using proprietary Micro Capture-C 3D genomics and machine learning to decode the non-coding genome and identify novel antibody drug targets for immune-mediated inflammatory diseases, with lead candidate NTP464 advancing toward Phase 1 in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D genomics platform, antibody therapeutics pipeline, non-coding genome decoding, inflammatory disease drug discovery, regulatory genome targeting
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology / Inflammatory Disease Drug Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Partnerships
TypeLicensing Royalties
Description

Nucleome is selectively partnering with pharmaceutical companies to identify targets and responsive patients in various therapeutic areas. Revenue would come from upfront payments, milestone payments, and royalties from partnership deals.

nucleome.com
2Drug Development and Commercialization
TypeOne Time License
Description

Developing proprietary pipeline of antibody therapeutics for inflammatory diseases with lead programme NTP464 in preclinical development. Revenue would come from product sales if drugs are approved and commercialized.

nucleome.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nucleome Therapeutics applies proprietary 3D genomics technology (Micro Capture-C) to decode the non-coding (regulatory) genome of the human genome and identify causal drug targets in inflammatory and autoimmune diseases. The company combines this platform with machine learning and functional genomics to build a proprietary disease atlas, discover novel therapeutic targets, and advance an internal pipeline of antibody therapeutics led by NTP464, while selectively partnering with pharmaceutical companies for target identification and co-development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 4x increase in clinical success rate for drug targets selected using Nucleome technology compared to industry standard
+2 more records
Product overview1 text field

Nucleome Therapeutics operates as an immunology company offering a proprietary 3D genomics platform combined with AI/ML capabilities to decode the regulatory (non-coding) genome for inflammatory disease drug discovery. The core product is the Micro Capture-C (MCC) Platform, which provides base-pair resolution mapping of 3D genomic interactions to identify functional disease variants and novel drug targets. The lead development candidate is NTP464, a first-in-class monoclonal antibody agonist for inflammation resolution currently in pre-clinical development. The company is building a pipeline of genetically-identified antibody therapeutics targeting inflammatory diseases.

Product and service2 records
1NTP464
CategoryTherapeutic pipeline - antibody candidate
Description

NTP464 is Nucleome's lead preclinical development candidate, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint for chronic inflammatory diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. It demonstrated efficacy in preclinical assays by inhibiting B cell, T cell, and macrophage activation while promoting Treg suppressive activities. Clinical trial application and Phase 1 commencement are targeted for 2027.

2Micro Capture-C (MCC) Platform
CategoryPlatform - 3D genomics target discovery technology
Description

The Micro Capture-C (MCC) Platform is Nucleome's proprietary 3D genomics technology that provides base-pair resolution mapping of chromatin interactions, physically linking regulatory elements in the non-coding genome to the genes they control. Exclusively licensed from Oxford University, it underpins the company's target identification work and is offered to pharmaceutical partners as the foundation of collaboration deals.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Weatherall Institute of Molecular Medicine, Oxford University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Collaborative research with Professor James Davies and researchers at the Weatherall Institute of Molecular Medicine resulted in a groundbreaking publication in Cell journal demonstrating base-pair resolution DNA folding and function using MCC technology.

prnewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Collaborated with Professor Rosana Collepardo-Guevara at University of Cambridge for computer simulations confirming that folding patterns observed in MCC technology arise naturally from the physical properties of DNA and its packaging proteins.

Strategic tierCoreTypeTechnology or Integration
Description

Nucleome holds an exclusive license from Oxford University to the Micro Capture-C (MCC) technology. The technology was developed by Professors Jim Hughes and James Davies at Oxford's Weatherall Institute of Molecular Medicine. Nucleome is actively collaborating with researchers at Oxford University, including a 2025 publication in Cell journal.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Nucleome is collaborating with a major pharmaceutical company and foresees multiple opportunities to collaborate with other companies to identify targets and responsive patients in various therapeutic areas.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleome Therapeutics

Biotechnology / Inflammatory Disease Drug Discoverynucleome.com

Nucleome Therapeutics is an Oxford University spinout using proprietary Micro Capture-C 3D genomics and machine learning to decode the non-coding genome and identify novel antibody drug targets for immune-mediated inflammatory diseases, with lead candidate NTP464 advancing toward Phase 1 in 2027.

What Nucleome Therapeutics does

Nucleome Therapeutics is a UK-based preclinical biotechnology company, spun out of the University of Oxford in 2019 and headquartered in Oxford, that decodes the non-coding ('dark') genome to identify causal drug targets for immune-mediated inflammatory diseases. Its proprietary Micro Capture-C (MCC) platform provides single base-pair resolution mapping of 3D chromatin interactions, physically linking non-coding disease-associated variants to the genes they dysregulate; MCC is exclusively licensed from Oxford University and protected by US Patent No. US12,674,197 (granted July 2026), with additional patents covering its Variant Functional Validation (VFV) technology granted in 2025. The company combines this wet-lab assay with deep-learning models and its proprietary 'Nucleome Genetic Score' to produce a Disease Atlas covering hundreds of dysregulated genes across multiple inflammatory cell types, and has retrospectively demonstrated a 4x improvement in clinical success rate over industry standard for drug target selection in inflammatory diseases.

The lead in-house programme is NTP464, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint, nominated in January 2026 for chronic inflammatory diseases including rheumatoid arthritis, lupus, and IBD, with IND-enabling studies underway and Phase 1 commencement targeted for 2027. Nucleome operates a dual business model: building its own antibody pipeline while selectively partnering with pharmaceutical companies — it has a current collaboration with a major (unnamed) pharma partner — to monetize targets, biomarkers, and patient stratification insights via licensing, milestone payments, and royalties. The company is venture-backed (Series A of £37.5M closed October 2022 led by M Ventures, with Pfizer Ventures, JJDC, British Patient Capital, and Oxford Science Enterprises) and led by an experienced team including CEO Dr. Mark Bodmer (formerly SVP at GSK and CSO at Evelo Biosciences), CSO Dr. Michelle Morrow (appointed February 2026), CTO Dr. Jonny Wray, and CBO Bhavna Hunjan.

Nucleome Therapeutics firmographics

Firmographics
Name
Nucleome Therapeutics
Legal name
Nucleome Therapeutics Limited
Website
https://nucleome.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Nucleome Therapeutics is an Oxford University spinout using proprietary Micro Capture-C 3D genomics and machine learning to decode the non-coding genome and identify novel antibody drug targets for immune-mediated inflammatory diseases, with lead candidate NTP464 advancing toward Phase 1 in 2027.
Ownership category
akta.pro rank

Nucleome Therapeutics industry classification

Industry
Product category
Biotechnology / Inflammatory Disease Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • 3D genomics platform
  • Antibody therapeutics pipeline
  • Non-coding genome decoding
  • Inflammatory disease drug discovery
  • Regulatory genome targeting

Where Nucleome Therapeutics is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Nucleome Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships: Nucleome is selectively partnering with pharmaceutical companies to identify targets and responsive patients in various therapeutic areas. Revenue would come from upfront payments, milestone payments, and royalties from partnership deals.
  2. Drug Development and Commercialization: Developing proprietary pipeline of antibody therapeutics for inflammatory diseases with lead programme NTP464 in preclinical development. Revenue would come from product sales if drugs are approved and commercialized.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Nucleome Therapeutics product offering

Product offering

Core offering

Nucleome Therapeutics applies proprietary 3D genomics technology (Micro Capture-C) to decode the non-coding (regulatory) genome of the human genome and identify causal drug targets in inflammatory and autoimmune diseases. The company combines this platform with machine learning and functional genomics to build a proprietary disease atlas, discover novel therapeutic targets, and advance an internal pipeline of antibody therapeutics led by NTP464, while selectively partnering with pharmaceutical companies for target identification and co-development.

Product overview

Nucleome Therapeutics operates as an immunology company offering a proprietary 3D genomics platform combined with AI/ML capabilities to decode the regulatory (non-coding) genome for inflammatory disease drug discovery. The core product is the Micro Capture-C (MCC) Platform, which provides base-pair resolution mapping of 3D genomic interactions to identify functional disease variants and novel drug targets. The lead development candidate is NTP464, a first-in-class monoclonal antibody agonist for inflammation resolution currently in pre-clinical development. The company is building a pipeline of genetically-identified antibody therapeutics targeting inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTP464 NTP464 is Nucleome's lead preclinical development candidate, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint for chronic inflammatory diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. It demonstrated efficacy in preclinical assays by inhibiting B cell, T cell, and macrophage activation while promoting Treg suppressive activities. Clinical trial application and Phase 1 commencement are targeted for 2027.
  • Micro Capture-C (MCC) Platform The Micro Capture-C (MCC) Platform is Nucleome's proprietary 3D genomics technology that provides base-pair resolution mapping of chromatin interactions, physically linking regulatory elements in the non-coding genome to the genes they control. Exclusively licensed from Oxford University, it underpins the company's target identification work and is offered to pharmaceutical partners as the foundation of collaboration deals.

Quantifiable outcome

  • 4x increase in clinical success rate for drug targets selected using Nucleome technology compared to industry standard
  • +2 more outcomes

Companies that use Nucleome Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Nucleome Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Nucleome Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, minor and major.

  • Weatherall Institute of Molecular Medicine, Oxford UniversitycoreStrategic or Co-development Partner · 6 November 2025Collaborative research with Professor James Davies and researchers at the Weatherall Institute of Molecular Medicine resulted in a groundbreaking publication in Cell journal demonstrating base-pair resolution DNA folding and function using MCC technology.
  • University of Cambridge - Professor Rosana Collepardo-GuevaraminorStrategic or Co-development Partner · 6 November 2025Collaborated with Professor Rosana Collepardo-Guevara at University of Cambridge for computer simulations confirming that folding patterns observed in MCC technology arise naturally from the physical properties of DNA and its packaging proteins.
  • Oxford UniversitycoreTechnology or IntegrationNucleome holds an exclusive license from Oxford University to the Micro Capture-C (MCC) technology. The technology was developed by Professors Jim Hughes and James Davies at Oxford's Weatherall Institute of Molecular Medicine. Nucleome is actively collaborating with researchers at Oxford University, including a 2025 publication in Cell journal.
  • Major Pharmaceutical Company (unnamed)majorStrategic or Co-development PartnerNucleome is collaborating with a major pharmaceutical company and foresees multiple opportunities to collaborate with other companies to identify targets and responsive patients in various therapeutic areas.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Nucleome Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Nucleome Therapeutics social profiles

Digital presence

Nucleome Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleome Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Nucleome Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleome Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleome Therapeutics

What does Nucleome Therapeutics do?

Nucleome Therapeutics applies proprietary 3D genomics technology (Micro Capture-C) to decode the non-coding (regulatory) genome of the human genome and identify causal drug targets in inflammatory and autoimmune diseases. The company combines this platform with machine learning and functional genomics to build a proprietary disease atlas, discover novel therapeutic targets, and advance an internal pipeline of antibody therapeutics led by NTP464, while selectively partnering with pharmaceutical companies for target identification and co-development.

Is Nucleome Therapeutics a public or private company?

Nucleome Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nucleome Therapeutics founded?

Nucleome Therapeutics was founded in 2019. It employs 51 to 100 people.

Where is Nucleome Therapeutics based?

Nucleome Therapeutics is headquartered in Oxford, United Kingdom, in the Europe region.

How does Nucleome Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Partnerships are the primary driver. The others are drug Development and Commercialization.

Does Nucleome Therapeutics have an API?

No public API is recorded for Nucleome Therapeutics.

What industry is Nucleome Therapeutics in?

Nucleome Therapeutics's product category is Biotechnology / Inflammatory Disease Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesNucleome Therapeutics strengthens global IP portfolio with US patent for core MCC TechnologyNucleome Therapeutics has received a US patent for its MCC technology, a core part of its 3D genomics platform, which it licensed from Oxford University. The company aims to decipher non-coding human disease genetics to develop targeted inflammatory disease medicines, including its lead program, NTP464.GlobeNewswireNucleome Therapeutics strengthens global IP portfolio with US patent for core MCC TechnologyNucleome Therapeutics, a UK-based biotechnology company focused on 3D genomics, has received US Patent No. US12,674,197 from the USPTO covering its Micro Capture-C (MCC) technology, the core platform for decoding non-coding disease genetics. The MCC technology, exclusively licensed from Oxford University, enables the company to map 3D genomic interactions that regulate gene expression and identify novel drug targets. The company's lead programme NTP464, a first-in-class monoclonal antibody for inflammation resolution, has entered IND-enabling studies.BioSpaceNucleome Therapeutics strengthens global IP portfolio with US patent for core MCC TechnologyNucleome Therapeutics received US patent US12,674,197 for its Micro Capture-C (MCC) 3D genomics technology. The patent covers the core of its platform, which links non-coding genetic variants to disease targets. The company's lead programme NTP464, a monoclonal antibody for inflammation, has initiated IND-enabling studies.PharmiWeb.comNucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific OfficerNucleome Therapeutics announced the appointment of Dr. Michelle Morrow as Chief Scientific Officer, effective 23 February 2026, following her departure from Avacta Therapeutics where she most recently served as CSO. Morrow brings over two decades of experience in drug discovery and development, having led oncology programs through to IND approval and held senior roles at invoX Therapeutics (following its acquisition of F-star Therapeutics) and MedImmune (now AstraZeneca). The appointment is intended to accelerate Nucleome's lead candidate NTP464, a monoclonal agonist antibody for inflammatory diseases, which is progressing toward IND-enabling studies.PR NewswireNucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific OfficerNucleome Therapeutics has appointed Dr. Michelle Morrow as Chief Scientific Officer, effective February 23, 2026, bringing two decades of experience in drug discovery and development from senior roles at Avacta Therapeutics, invoX Therapeutics (following its acquisition of F-star Therapeutics), and MedImmune (now AstraZeneca). The appointment follows Nucleome's nomination of its first preclinical development candidate for lead programme NTP464, a novel monoclonal agonist antibody for inflammatory diseases currently progressing toward IND-enabling studies. Dr. Morrow's expertise in immunology and bispecific antibody therapeutics is expected to strengthen the company's pipeline advancement and decision-making capabilities.PR NewswireNucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific OfficerNucleome Therapeutics announced the appointment of Dr. Michelle Morrow as Chief Scientific Officer, effective February 23, 2026, bringing two decades of experience in drug discovery and development from roles at Avacta Therapeutics, invoX Therapeutics, and MedImmune (now AstraZeneca). Dr. Morrow previously led Avacta's oncology programme through candidate selection to IND approval and brings expertise in immunology and bispecific antibody therapeutics. The appointment is expected to accelerate Nucleome's lead candidate NTP464, a novel monoclonal agonist antibody for inflammatory diseases currently progressing toward IND-enabling studies.PR NewswireNucleome Therapeutics nominates first preclinical development candidateNucleome Therapeutics has nominated its first preclinical development candidate, NTP464, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint for chronic inflammatory diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. The company's proprietary Micro Capture-C platform combined with machine learning has enabled it to build a comprehensive atlas of molecular drivers of inflammatory diseases, and NTP464 has demonstrated efficacy in preclinical assays by inhibiting B cell, T cell, and macrophage activation while promoting Treg suppressive activities. The programme will now progress towards IND enabling studies, and the company highlighted that several new patents were granted in 2025 protecting its core technologies.PharmiWeb.comNucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal CellNucleome Therapeutics founder Professor James Davies and researchers at Oxford University's Weatherall Institute of Molecular Medicine have published a paper in Cell journal demonstrating the most detailed view yet of how DNA folds and functions inside living cells at base-pair resolution using Micro Capture-C technology. The MCC technology physically identifies contacts between regulatory elements in the non-coding genome and the genes they control, enabling the decoding of gene expression regulation at scale to identify new drug targets. Nucleome holds an exclusive license from Oxford University to the MCC technology and has applied it to decipher molecular basis of inflammatory diseases from thousands of non-coding disease-associated genetic variants.PR NewswireNucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal CellNucleome Therapeutics and Oxford University researchers published a paper in Cell demonstrating the first detailed view of DNA folding and function inside living cells at base pair resolution using Micro Capture-C (MCC) technology. The breakthrough reveals how regulatory elements in the non-coding genome interact with the genes they control, enabling large-scale identification of new drug targets for inflammatory diseases. Nucleome holds exclusive licensing rights to the MCC technology from Oxford University and is using this approach to build a pipeline of antibody therapeutics based on human disease genetics.